AI Medical Startup NeuroXTI Collaborates with Harvard University Hospital on Alzheimer's Treatment Research

Bio startup ‘NeuroXT’ recently announced on the 26th that it is strengthening its partnership for joint research with BIDMC, a hospital affiliated with Harvard Medical School in the United States.

Sung Jun-kyung, CEO of NeuroXTI

The core goal of the joint research is to clinically validate the effectiveness of an ‘Artificial Intelligence (AI) Imaging Biomarker Solution’ that predicts treatment outcomes for Alzheimer’s patients. Research to establish related treatment guidelines will also be conducted.

NeuroXT focuses on developing AI-based brain imaging biomarker analysis technology that can clearly predict the treatment effectiveness of Alzheimer’s drugs for each patient. This technology analyzes brain magnetic resonance imaging (MRI) results during the Alzheimer’s treatment planning stage. In particular, it predicts treatment outcomes based on the interaction of beta-amyloid and tau proteins, which are known to cause Alzheimer’s dementia. The core mechanism was published in 2022 in Neuron, a journal of CELL, one of the world’s top three scientific journals.

Seong Jun-kyung, CEO of NeuroXT, stated, “This technology will establish itself as the first-ever imaging biomarker technology capable of pre-diagnosing the suitability of treatment for individual patients in the Alzheimer’s treatment market,” and added, “Furthermore, it will provide excellent future value not only to patients and medical staff but also to pharmaceutical companies and health insurers.” He also mentioned, “Clinical validation is underway through actual treatment data of patients at a major hospital in the United States.”

NeuroXT plans to jointly conduct clinical validation and develop patient-customized Alzheimer’s treatment guidelines through an agreement with BIDMC. BIDMC is known as the first medical institution registered under Medicare’s conditional insurance. Daniel Press, a BIDMC professor and a leading authority in Alzheimer’s treatment, said, “Through this collaboration, we will lead the era of Alzheimer’s treatment,” and “We will be able to establish a new paradigm of patient-customized dementia treatment based on treatment outcome prediction through NeuroXT’s AI-based predictive biomarker.”

CEO Seong said, “Imaging biomarker-based companion diagnostic AI technology has already been proven necessary in the field of cancer immunotherapy,” and added, “In the future, Alzheimer’s dementia treatment will follow a similar path,” expressing high expectations for the future value of this technology.

Since its founding in 2022, NeuroXT has attracted seed (early-stage) investments from Ajou IB Investment and Mira Ventures, and last year secured Pre-A series investments from Kakao Ventures, Daily Partners, Smilegate Investment, and Korea Investment Accelerator.

This content was produced with the assistance of AI translation services.